What does “Calquence EMA approval” refer to?
“Calquence” is the brand name for acalabrutinib. “EMA approval” means the European Medicines Agency has granted marketing authorization for a specific use (indication) in the EU/EEA, which can include approval for new patient groups or new combinations as the label expands. The exact approval depends on the indication and date.
For which Calquence indication(s) was it approved by the EMA?
The EMA authorizes Calquence for defined blood-cancer settings (typically B-cell malignancies). Which one you mean matters because Calquence’s EMA label has expanded over time (for example, by adding combinations or additional disease subtypes).
When did the EMA approve Calquence?
EMA approval timing depends on the first authorization versus later label updates. The first approval date is different from subsequent approvals that add indications or change treatment combinations.
Is Calquence approved across all EU countries?
EMA marketing authorization is valid across EU/EEA member states, but local country reimbursement, prescribing rules, and availability can still vary.
If you’re checking approval status now, how to verify the current EMA label
The most reliable way to confirm “EMA approval” for Calquence is to check the EMA product information (the authorized SmPC and package leaflet), which shows the current, approved indications and any restrictions.
If you tell me which context you mean—initial approval date, a specific indication (e.g., CLL or another), or a particular combination—I can narrow the answer to that exact EMA approval.
Sources
I don’t have the EMA approval details (dates/indications) in the provided information, so I can’t cite them accurately.